Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Institut Paoli-Calmettes
Sponsor

Institut Paoli-Calmettes

France 232 Boulevard De Sainte Marguerite, Bp 156, 13009 Marseille, France

About the sponsor

Clinical research at Institut Paoli Calmettes is strongly centred on acute myeloid leukaemia, relapsed/refractory acute leukaemia, and other high-risk myeloid malignancies, with additional activity in broader haematological malignancies.

  • Acute myeloid leukaemia
  • Relapsed/refractory acute leukaemia
  • Myelodysplastic syndromes
  • High-risk myeloid malignancies

Research interest includes treatment-resistant disease, post-remission management, and transplant-related care in patients with aggressive blood cancers.

About Specializations

Institut Paoli-Calmettes runs clinical trials in conditions such as Acute myeloid leukaemia, HER2 negative breast cancer, Breast cancer, Haematological malignancy, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

9 clinical trials

Acute myeloid leukaemia

Recruiting

Study on Stopping Venetoclax and Azacitidine in Patients with Acute Myeloid Leukemia Who Are Responding to Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Institut Paoli-Calmettes

HER2 negative breast cancer

Recruiting

Study of Pembrolizumab with Chemotherapy for Patients with HER2-Negative Inflammatory Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Institut Paoli-Calmettes

Breast cancer

Recruiting

Study of Tuvusertib and Fulvestrant for Advanced Breast Cancer Resistant to CDK4/6 and Aromatase Inhibitors in Hormone Receptor-Positive, HER2-Negative Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Institut Paoli-Calmettes

Haematological malignancy+1

Recruiting

Study on Enhanced GVH Prevention in Elderly Patients with Blood Cancer Using Rabbit Anti-Human Thymocyte Immunoglobulin During Stem Cell Transplantation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rabbit Anti-Human Thymocyte Immunoglobulin
  • Sponsor:Institut Paoli-Calmettes

Bladder cancer

Not yet recruiting

Feasibility of Photodynamic Diagnosis Using Intravesical Hexaminolevulinate with Sub‑One‑Hour Instillation in Patients with Primary or Recurrent Papillary Bladder Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Hexaminolevulinate
  • Sponsor:Institut Paoli-Calmettes

Acute myeloid leukaemia

Not yet recruiting

Fludarabine with drug combination for older or frail patients with acute myeloid leukemia undergoing haploidentical stem cell transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ciclosporin
  • Sponsor:Institut Paoli-Calmettes

Triple negative breast cancer

Not yet recruiting

Carboplatin drug combination as neoadjuvant therapy for early stage II triple‑negative breast cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Institut Paoli-Calmettes

Acute myeloid leukaemia

Not yet recruiting

Study of Dasatinib for Patients with Acute Myeloid Leukemia Not Responding to Venetoclax-Azacitidine Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dasatinib
  • Sponsor:Institut Paoli-Calmettes

Acute myeloid leukaemia+1

Not recruiting

Study of three different doses of busulfan with fludarabine and thymoglobuline in stem cell transplantation for patients with high-risk myeloid blood disorders

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Busulfan
  • Sponsor:Institut Paoli-Calmettes

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.